

Anurag Relan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039188/publications.pdf>

Version: 2024-02-01

36
papers

963
citations

430754

18
h-index

434063

31
g-index

36
all docs

36
docs citations

36
times ranked

517
citing authors

#	ARTICLE	IF	CITATIONS
1	Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 821-827.e14.	1.5	203
2	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 112, 163-169.e1.	0.5	70
3	Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 359-366.	1.5	63
4	Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 506-513.	2.7	62
5	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. <i>Lancet, The</i> , 2017, 390, 1595-1602.	6.3	55
6	Target levels of functional C1-inhibitor in hereditary angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 123-130.	2.7	51
7	Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 295-299.	0.5	51
8	Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. <i>Clinical and Experimental Allergy</i> , 2012, 42, 929-935.	1.4	50
9	Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 118-124.	2.7	38
10	Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 417-423.	2.0	32
11	Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 897-907.	1.1	29
12	Recombinant C1-Inhibitor. <i>BioDrugs</i> , 2012, 26, 43-52.	2.2	28
13	Clinical Impact of Peripheral Attacks in Hereditary Angioedema Patients. <i>American Journal of Medicine</i> , 2012, 125, 937.e17-937.e24.	0.6	22
14	Hereditary Angioedema Attacks: Local Swelling at Multiple Sites. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 50, 34-40.	2.9	22
15	C-reactive protein levels in hereditary angioedema. <i>Clinical and Experimental Immunology</i> , 2014, 177, 280-286.	1.1	20
16	Immunogenicity Assessment of Recombinant Human C1-Inhibitor. <i>BioDrugs</i> , 2012, 26, 303-313.	2.2	19
17	Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema. <i>Patient</i> , 2012, 5, 113-126.	1.1	18
18	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. <i>Pediatric Allergy and Immunology</i> , 2019, 30, 562-568.	1.1	18

#	ARTICLE	IF	CITATIONS
19	C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury. <i>Shock</i> , 2016, 46, 177-188.	1.0	16
20	Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies. <i>Clinical Drug Investigation</i> , 2013, 33, 275-281.	1.1	14
21	Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2938-2940.	2.0	14
22	Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 462-466.	1.0	13
23	Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 452-455.	0.5	12
24	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1091-1097.	2.0	9
25	Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 359-364.	1.0	9
26	Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 456-461.	1.0	8
27	Immunogenicity Assessment of Recombinant Human C1-Inhibitor. <i>BioDrugs</i> , 2012, 26, 303-313.	2.2	6
28	Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 476-481.e1.	1.5	3
29	Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry. <i>World Allergy Organization Journal</i> , 2021, 14, 100535.	1.6	3
30	Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 203-210.	0.5	2
31	Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB37.	1.5	1
32	C1 esterase inhibitor concentrates and attenuated androgens – Authors' reply. <i>Lancet, The</i> , 2018, 391, 1356.	6.3	1
33	Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 707-712.	0.5	1
34	Immuno-Safety of Recombinant Human C1 Inhibitor in Patients With Hereditary Angioedema. <i>World Allergy Organization Journal</i> , 2012, 5, S28.	1.6	0
35	Recombinant Human C1 Inhibitor Treatment Does Not Affect D-Dimer Levels and Is Not Associated With Thromboembolic Events In HAE Patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB36.	1.5	0
36	Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks. <i>Journal of Drug Assessment</i> , 2019, 8, 22-22.	1.1	0